jueves, 26 de marzo de 2015

Press Announcements > FDA approves new treatment for diabetic retinopathy in patients with diabetic macular edema

Press Announcements > FDA approves new treatment for diabetic retinopathy in patients with diabetic macular edema

FDA Division of Drug Information: Know the Moment It Happens



The U.S. Food and Drug Administration today expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema.
Diabetic retinopathy (DR) is the most common diabetic eye disease and is a leading cause of blindness in adults in the United States. According to the Centers for Disease Control and Prevention, diabetes (type 1 and type 2) affects more than 29 million people in the United States and is the leading cause of new blindness among people ages 20 to 74 years. In 2008, 33 percent of adults with diabetes aged 40 years or older had some form of DR. In some cases of DR with diabetic macular edema (DME), abnormal new blood vessels grow on the surface of the retina. Severe vision loss or blindness can occur if the new blood vessels break.
To learn more, please visit: Eylea.

No hay comentarios:

Publicar un comentario